Skin Cancer Early Detection Rates Increased with Teledermatology
- Case Study Players
- MedX: On a Mission to Deliver World Class Imaging Providing Better Patient Outcomes
- MedX Sources Blanc Labs as Platform Development Partner
- Blanc Labs, Powered by Smile CDR Brings MedX Teledermatology Platform to Life in Record Time
- MedX's Early Detection Capabilities Reduce Anxiety, Save Lives
Skin cancer is one of the most commonly diagnosed–and deadliest–cancers in the world. Early stage melanoma has well-documented treatment protocols with a high rate of success with up to a 99% survival rate. However, when suspicious moles or skin lesions go undiagnosed, a patient’s chance of survival can plummet.
To solve the problem of late diagnoses and to save more lives, MedX, the creator of the medical imaging device SIAscope, sought to deploy a teledermatology platform that would securely transmit their high quality images for dermatologists to assess.
MedX partnered with Blanc Labs to upgrade their software from an antiquated PC-based system to a browser-based platform capable of storing and sharing data securely on the cloud. Blanc Labs identified Smile CDR as the strategic HL7 FHIR partner that could help enable MedX’s global expansion and interoperability requirements.
Within two years, MedX’s teledermatology platform serviced tens of thousands of patients across three continents. Now, patients and physicians can receive accurate diagnoses of suspicious moles and skin lesions in two days instead of weeks or months. Patients can get the life-saving early intervention they need with the streamlined and simplified experience MedX provides for both the patient and clinician.